MX2019014059A - Adenovirus antiangiogenico. - Google Patents
Adenovirus antiangiogenico.Info
- Publication number
- MX2019014059A MX2019014059A MX2019014059A MX2019014059A MX2019014059A MX 2019014059 A MX2019014059 A MX 2019014059A MX 2019014059 A MX2019014059 A MX 2019014059A MX 2019014059 A MX2019014059 A MX 2019014059A MX 2019014059 A MX2019014059 A MX 2019014059A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- angiostatin
- combination
- adenovirus
- endostatin
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 title 1
- 102400000068 Angiostatin Human genes 0.000 abstract 2
- 108010079709 Angiostatins Proteins 0.000 abstract 2
- 102400001047 Endostatin Human genes 0.000 abstract 2
- 108010079505 Endostatins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00041—Use of virus, viral particle or viral elements as a vector
- C12N2710/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510647P | 2017-05-24 | 2017-05-24 | |
| US201762514351P | 2017-06-02 | 2017-06-02 | |
| PCT/US2018/034487 WO2018218083A1 (en) | 2017-05-24 | 2018-05-24 | Anti-angiogenic adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014059A true MX2019014059A (es) | 2020-07-28 |
Family
ID=64396026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014059A MX2019014059A (es) | 2017-05-24 | 2018-05-24 | Adenovirus antiangiogenico. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200155625A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3630959A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7245175B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200020723A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111448309A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018271999A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3064892A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2019014059A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018218083A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN110295195A (zh) * | 2019-06-26 | 2019-10-01 | 浙江理工大学 | 靶向肝癌的溶瘤腺病毒gd55-gsdme的构建和应用 |
| US20230235355A1 (en) * | 2020-06-05 | 2023-07-27 | Epicentrx, Inc. | Mono- and multi-valent sars-cov- 2 adenoviral vector vaccines and sars-cov-2 immune globulin and methods of use |
| CN115120744B (zh) * | 2021-03-24 | 2025-01-28 | 四川大学 | 重组人内皮抑素腺病毒与抗pd-1抗体或抗pd-l1抗体在制备抗肿瘤药物中的用途 |
| CN114931634B (zh) * | 2022-03-18 | 2023-03-17 | 广州达博生物制品有限公司 | E10a与pd1单抗对肿瘤的联合治疗方法和制药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| EP1437938A2 (en) * | 2001-04-30 | 2004-07-21 | Cell Genesys, Inc. | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| EP1831382B1 (en) * | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| DK2403951T3 (en) * | 2009-03-02 | 2016-01-11 | Univ California | Tumor-selective E1a and E1b adenoviral mutants |
| CA3052090A1 (en) * | 2017-01-30 | 2018-08-02 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
-
2018
- 2018-05-24 MX MX2019014059A patent/MX2019014059A/es unknown
- 2018-05-24 WO PCT/US2018/034487 patent/WO2018218083A1/en not_active Ceased
- 2018-05-24 CN CN201880051792.1A patent/CN111448309A/zh active Pending
- 2018-05-24 CA CA3064892A patent/CA3064892A1/en active Pending
- 2018-05-24 US US16/616,146 patent/US20200155625A1/en not_active Abandoned
- 2018-05-24 AU AU2018271999A patent/AU2018271999A1/en not_active Abandoned
- 2018-05-24 KR KR1020197037967A patent/KR20200020723A/ko not_active Ceased
- 2018-05-24 EP EP18806701.1A patent/EP3630959A4/en not_active Withdrawn
- 2018-05-24 JP JP2019565334A patent/JP7245175B2/ja active Active
-
2023
- 2023-03-10 JP JP2023037694A patent/JP2023063392A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023063392A (ja) | 2023-05-09 |
| EP3630959A1 (en) | 2020-04-08 |
| CA3064892A1 (en) | 2018-11-29 |
| WO2018218083A1 (en) | 2018-11-29 |
| CN111448309A (zh) | 2020-07-24 |
| EP3630959A4 (en) | 2021-03-17 |
| AU2018271999A1 (en) | 2020-01-16 |
| US20200155625A1 (en) | 2020-05-21 |
| JP7245175B2 (ja) | 2023-03-23 |
| JP2020521470A (ja) | 2020-07-27 |
| KR20200020723A (ko) | 2020-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MD20170073A2 (ro) | Terapii combinate pentru tratarea cancerelor | |
| MX2024014238A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2017014797A (es) | Metodos y kits para tratar la depresion. | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| MX2019009753A (es) | Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| EP4640237A3 (en) | Macrophage-based therapy for use in the treatment of acute liver injury | |
| PH12018550186A1 (en) | Pharmaceutical combinations for treating cancer | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| PH12019502578A1 (en) | Methods of treatment for cervical dystonia | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2021002668A (es) | Plataforma de virus oncolitico para tratar el cancer hematologico. | |
| MX2019006551A (es) | Terapia génica para mucopolisacaridosis de tipo ii. | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. |